Short-term antihypertensive efficacy of perindopril according to clinical profile of 3,188 patients: A meta-analysis

Cardiology Journal

Volumn 17, Issue 3, 2010, Pages 259-266

  Gasowski, Jerzy ^a   Wilkins, Arleta ^b   Drzewoski, Józef ^c   Kłoś, Jadwiga ^d   Gaciong, Zbigniew ^e   Kabat, Marek ^f   Grodzicki, Tomasz ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b Servier Polska   (Poland)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d GROCHOWSKI HOSPITAL   (Poland)

^e MEDICAL UNIVERSITY OF WARSAW   (Poland)

^f INSTITUTE OF CARDIOLOGY   (Poland)

Author keywords

Efficacy; Hypertension; Meta analysis; Perindopril

Indexed keywords

INDAPAMIDE; PERINDOPRIL; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGE; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; META ANALYSIS; SEX DIFFERENCE; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; ADULT; BLOOD PRESSURE; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; FEMALE; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); PATHOPHYSIOLOGY; POLAND; TIME; TREATMENT OUTCOME;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PERINDOPRIL; POLAND; TIME FACTORS; TREATMENT OUTCOME;

EID: 77953350443     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet, 1990; 335: 765-774.
2. Asia Pacific Cohort Studies Collaboration. Blood pressure indices and cardiovascular disease in the Asia Pacific region. A pooled analysis. Hypertension, 2003; 42: 69-75.
3. Staessen JA, Wang J, Bianchi G, Birkenhäger WH. Essential hypertension. Lancet, 2003; 361: 1629-1641.
4. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet, 1990; 335: 827-838.
5. Staessen JA, Gasowski J, Wang JG et al. Risks of untreated and treated isolated systolic hypertension in the elderly: Meta-analysis of outcome trials. Lancet, 2000; 355: 865-872.
6. Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: An update including the 2003-2004 secondary prevention trials. Hypertens Res, 2005; 28: 385-407.
7. Progress Collaborative Group. Randomised trial of a perindopril--based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet, 2001; 358: 1033-1041.
8. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet, 2003; 362: 782-788.
9. Drzewoski J, Cwiok A, Drewla J, Kaminski J. Assessment of 24- -hour antihypertensive eficacy of perindopril in mild-to-moderate hypertensive patients: Part 2. Polish Perindopril Assessment Programme. Klinika, 1998; 3: 281-286.
10. Antihypertensive treatment in obese patients. Results of Polish Perindopril Assessment Programme 3. Infomedica, 1998; 3: 13.
11. Klos J, Suchecka-Rachon K, Cybulska K, Wilkins A. Efficacy and tolerability of perindopril in the treatment of essential hypertension in postmenopausal women. Arterial Hypertens, 2004; 8: 263-271.
12. Gaciong Z, Czech A, Symonides B, Wlodarczyk P. Efficacy of perindopril monotherapy in hypertension associated with well controlled type 2 diabetes mellitus. Diabetol Pol, 2004; 11: 217-226.
13. Morgan T, Anderson A, Wilson D, Murphy J, Nowson C. The effect of perindopril on blood pressure in humans on different sodium intakes. J Cardiovasc Pharmacol, 1987; 10 (suppl. 7): S116-S118.
14. Thurston H, Mimran A, Zanchetti A et al. A double blind comparison of perindopril and atenolol in essential hypertension. J Hum Hypertens, 1990; 4: 547-552.
15. Morgan TO, Louis WJ, MacDonald GJ et al. Antihypertensive efficacy and safety of perindopril in mild-to-moderate essential hypertension: results of a double-blind multicenter study versus atenolol. Am J Med, 1992; 92: 73S-78S.
16. Thurston H, Desche P. Assessment of antihpertensive efficacy of perindopril: Results of double blind multicenter studies versus reference drugs. J Cardiovasc Pharmacol, 1991; 18 (suppl. 7): S45-S49.
17. Alcocer L, Campos C, Bahena JH et al. Clinical acceptability of ACE inhibitor therapy in mild to moderate hypertension, a comparison between perindopril and enalapril. Cardiovasc Drugs Ther, 1995; 9: 431-436.
18. Bussien JP, d'Amore TF, Perret L et al. Single and repeated dosing of the converting enzyme inhibitor perindopril to normal subjects. Clin Pharmacol Ther, 1986; 39: 554-558.
19. Julius S, Cohn JN, Neuthel JM et al. Antihypertensive utility of perindopril in a large general practice-based clinical trial. J Clin Hypertens (Greenwich), 2004; 6: 10-17.
20. Guo W, Turlapaty P, Shen Y et al. Clinical experience with perindopril in patients nonresponsive to previous antihypertensive therapy: A large US community trial. Am J Ther, 2004; 11: 199-205.
21. Leenen FH, Tanner J, McNally CF. Antihypertensive efficacy of the ACE-inhibitor perindopril in the elderly. J Hum Hypertens, 2000; 14: 321-325.
22. Neuthel JM, Weber MA, Julius S et al. Clinical experience with perindopril in elderly hypertensive patients: A subgroup analysis of a large community trial. Am J Cardiovasc Drugs, 2004; 4: 335-341.